Research institution
Tianjin Medical University Cancer Institute and Hospital Clinical Trials
Studies where Tianjin Medical University Cancer Institute and Hospital is the lead sponsor: what is enrolling now, by phase, condition and country.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 219Small Cell Lung Cancer (SCLC), SCLC, Extensive Stage
Low-Dose Radiotherapy Plus Adebrelimab and Chemotherapy for Extensive-Stage Small Cell Lung Cancer
This is a phase II study evaluating a novel combination therapy for untreated extensive-stage small cell lung cancer. The treatment involves an initial induction phase with the drug Adebrelimab plus standard chemotherapy and…
- Trial name
- NCT07909863
- Testing
- Adebrelimab + Chemotherapy + Radiotherapy
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Non-Small Cell Carcinoma of Lung
Single-center Transformational Study on Feasibility and Efficacy of Respiratory Motion Management Using Novel Position Fixation Device for Lung Cancer Patients Undergoing Stereotactic Body Radiation Therapy(2023 No.358 Project)
This single-center study evaluates a novel body position and breath-holding device for lung cancer patients receiving stereotactic body radiation therapy.
- Trial name
- NCT07916129
- Testing
- Novel Respiratory Immobilization Device for Lung SBRT
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cervical Cancer
Hydrogel Spacer During Definitive Radiotherapy for Cervical Cancer
This prospective, single-center study will evaluate the feasibility, spatial stability, and dosimetric effects of an absorbable hydrogel spacer placed between the cervix/vagina and rectum before definitive radiotherapy for…
- Trial name
- Hydrogel-RT (NCT07904182)
- Testing
- Absorbable Hydrogel Spacer
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Squamous Cell Carcinoma (ESCC)
Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
This study is a prospective, randomized controlled, phase III multicenter trial. Its objectives are to explore the stratified application of consolidation immunotherapy after chemoimmunotherapy induction plus concurrent…
- Trial name
- NCT07246330
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 340 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Chronic Pain, Postoperative
Effect of Low-Dose Esketamine Combined With Dexmedetomidine on the Incidence of Chronic Postsurgical Pain in Patients Undergoing Pancreatic Surgery
The goal of this clinical trial is to learn if low-dose esketamine combined with dexmedetomidine can reduce chronic pain after pancreatic surgery in adults. It will also learn about its safety.
- Trial name
- NCT07888413
- Testing
- Esketamine combined with dexmedetomidine
- Volunteers
- 450 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Endometrial Adenocarcinoma, Endometrial Cancer
QL1706-Based Therapy Post-PD-1/L1 Failure in Advanced Endometrial Cancer
This is a prospective, single-arm, multicenter Phase II study evaluating the efficacy and safety of QL1706 combined with chemotherapy in patients with advanced recurrent or metastatic endometrial cancer who progressed after prior…
- Trial name
- QLPPEC/GOG-003 (NCT06917092)
- Testing
- QL1706 combined with chemotherapy ± Bevacizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Esophageal Cancer
dCRT vs. Surgery in Resectable ESCC Patients Achieving cCR/PR After Induction Chemoimmunotherapy
This study is evaluating two treatment approaches for patients with locally advanced, resectable esophageal squamous cell carcinoma (ESCC) who have a good response to 2-3 cycles of induction chemoimmunotherapy.
- Trial name
- SORT (NCT07162506)
- Testing
- Surgery, Radiotherapy, Chemotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Advanced Hepatocellular Carcinoma (HCC)
Fecal Microbiota Transplantation Combined With QL1706 Plus Bevacizumab for Advanced HCC
This is a prospective, single-center, single-arm Phase II pilot study designed to evaluate the efficacy and safety of FMT in combination with QL1706 and Bevacizumab as first-line treatment for advanced Hepatocellular carcinoma.
- Trial name
- NCT07847671
- Testing
- FMT combined with QL1706 plus Bevacizumab
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Pediatric Cancer, Solid Tumor Cancer
Umbilical Cord Blood Infusion to Promote Hematopoietic and Immune Reconstitution in Children With Relapsed or Refractory Malignant Solid Tumors
Pediatric malignant solid tumors (including neuroblastoma, Wilms tumor, hepatoblastoma, rhabdomyosarcoma, osteosarcoma, Ewing sarcoma, and germ cell tumors) account for approximately 60% of childhood malignancies.
- Trial name
- NCT07866534
- Testing
- umbilical cord blood
- Volunteers
- 10 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
Fecal Microbiota Transplantation Combined With NALIRIFOX Plus Serplulimab as First-line Treatment for Advanced or Metastatic Pancreatic Ductal Adenocarcinoma.
This single center, prospective, randomized, open-label, two-arm parallel-controlled Phase II clinical trial is designed to evaluate the efficacy and safety of fecal microbiota transplantation （FMT ）combined with Nalirifox plus…
- Trial name
- NCT07854977
- Testing
- FMT combined with chemotherapy plus immunotherapy, Chemotherapy+Immunotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital